ClinicalTrials.gg
CompletedNCT05125588Updated Nov 18, 2021

Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition

A Phase 1 interventional study of Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine) and Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece) in Pharmacokinetics, sponsored by Joint Stock Company "Farmak". Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Joint Stock Company "Farmak" · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 7 years 9 months after the study started (first participant enrolled Jan 2014, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of the study was to compare the bioavailability of two formulations of meloxicam given to healthy volunteers and to demonstrate bioequivalence. The test product, Reumoxicam® 15 mg tablets (Farmak PJSC, Ukraine), given in a single dose was compared with a licensed reference product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece), in a randomized, laboratory-blind, single dose, two periods, crossover study.

The secondary objective of the trial was to investigate the safety of both preparations on the basis of safety clinical and laboratory examinations (at the beginning and at the end of the trial) and registration of adverse events and/ or adverse drug reactions.

Read the detailed description

Randomized, single-dose, crossover, two-period, two-sequence, laboratory-blinded, comparative bioavailability study of test medicinal product Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine) and reference medicinal product Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece) in healthy volunteers under fasting condition.

During each period 18 blood samples were taken: before dosing (0) and then at: 0.5; 1; 2; 3; 4; 4.5; 5; 5.5; 6; 7; 8; 10; 12; 24; 36; 48 and 72 hours after dosing.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • bioequivalence
  • pharmacokinetics
  • generic drugs
  • Meloxicam
03

In context

Lead sponsor

Joint Stock Company "Farmak" is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy volunteers, men and women aged 18 to 45 years (inclusive);
  2. Provided written Form of a Healthy Volunteer for Participation in the Clinical Study before the beginning of any screening procedures;
  3. Ability (to the opinion of the investigator) to fulfill all requirements of the Study Protocol, i.e. the volunteer's ability for adequate collaboration;
  4. is within the limits (> 18,5 kg/m2 and \< 30,0 kg/m2);
  5. Persons free from any acute and chronic diseases of cardiovascular system, neuroendocrine system, kidneys, liver, gastrointestinal tract, and respiratory system;
  6. Results of physical, instrumental, and laboratory examination of volunteers are within the normal limits, or any deviations are classified by the investigator as clinically irrelevant;
  7. Chest fluorography or radiography results are within the normal limits (the examination should be carried out no earlier than 9 months before the screening moment), or any deviation is classified by the investigator as clinically irrelevant;
  8. Women and men have to use medically confirmed barrier method of during the whole study period;
  9. Volunteers have to be non-smokers or smoke up to 10 cigarettes a day inclusive;
  10. Volunteers need to undertake to follow all general diet limitations during the whole study period.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with evidence or suspicion of any relevant clinical abnormality (as based on medical history, physical examination, vital signs, chest X-ray, and 12-lead )
  2. Known to meloxicam and/or other products ingredients;
  3. Compromised allergologic history;
  4. Subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs;
  5. Active peptic ulcer, gastrointestinal perforation or bleeding within the last 6 months;
  6. Subjects with peripheral oedema;
  7. Any previously incurred diseases or surgical interventions which, to the investigator's opinion, may affect pharmacokinetics of the investigational product;
  8. Positive result of , syphilis, and C markets test;
  9. Positive result of urine test for narcotic substances (amphetamine, metamphetamine, morphine, marijuana, cocaine);
  10. Positive result of alcohol vapors test in expired air;
  11. Pregnancy (positive result of urine pregnancy test in women) and lactation period;
  12. Incurred acute infectious diseases within 28 days before beginning of the study;
  13. Use of any medicinal products within 14 days before beginning of the study;
  14. Blood donation or blood loss of more than 300 ml in less than 30 days before beginning of the study;
  15. Participation in any other clinical study during the last 90 days before beginning of the study;
  16. Other reasons which, to the investigator's opinion, make the volunteer's participation in the study undesirable.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A

    Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine)

    Drug: Reumoxicam® 15 mg tablets (PJSC "Farmak", Ukraine)

  • Active comparator
    Treatment B

    Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)

    Drug: Movalis 15 mg tablets ("Boehringer Ingelheim Ellas A.E.", Greece)

Interventions

  • One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

    Also known as: Meloxicam

  • One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.

    Also known as: Meloxicam

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the plasma concentration-time curve from time zero to time t of the last quantifiable concentration

    Time frame: up to 72 hours post-administration

  2. Cmax

    Maximum drug concentration in plasma

    Time frame: up to 72 hours post-administration

Secondary outcomes

  1. AUC0-inf

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: up to 72 hours post-administration

  2. tmax

    time after administration to reach maximum drug concentration in plasma

    Time frame: up to 72 hours post-administration

  3. t1/2

    elimination half-life

    Time frame: up to 72 hours post-administration

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Feb 2014, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 18, 2021
StartActual
Jan 29, 2014
Primary completionActual
Feb 26, 2014
CompletionActual
Feb 26, 2014
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05125588
Lead sponsor
Joint Stock Company "Farmak"
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Jan 29, 2014
Primary completion
Feb 26, 2014
Completion
Feb 26, 2014
Last update
Nov 18, 2021

Study contacts

Vlad Udovytskyi
study chair · Joint Stock Company "Farmak"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion